Anti-Factor VII Anticorps [F7/3512] (A314947)

Anti-Factor VII Antibody [F7/3512]

Mouse monoclonal [F7/3512] antibody to Factor VII.

Hemostasis following tissue injury involves the deployment of essential plasma procoagulants (prothrombin and Factors X, IX, V and VIII), which are involved in a blood coagulation cascade that leads to the formation of insoluble Fibrin clots and the promotion of platelet aggregation. Coagulation Factor VII (serum prothrombin conversion accelerator, proconvertin, F7, Factor VII) is a 406 amino acid, vitamin K-dependent, single chain serine protease that is synthesized in the liver and circulates as an inactive precursor. Factor IX A, Factor X A, Factor XII A or Thrombin-mediated proteolytic cleavage of Factor VII at Arg 152-Ile 153 generates Factor VII A, an active serine protease composed of a catalytic heavy chain disulfide linked to a light chain, containing two EGF-like domains. Mutations at the F7 locus that lead to Factor VII deficiencies are generally asymptomatic or phenotypically uncharacterized, with hemorrhagic diathesis occurring at extremely low levels.

ELISA, IHC-P

Human liver or gastric carcinoma.

IHC: 1-2 µg/ml

Human

Recombinant fragment (around Amino Acids 366-466) of human F7 protein.

Mouse

Monoclonal

F7/3512

kappa

Unconjugated

Protein A/G chromatography.

200 µg/ml

200 kDa / 80 kDa / 73 kDa / 50 kDa / 43 kDa

Liquid

Supplied in 10mM Phosphate Buffered Saline with 0.05% BSA and 0.05% Sodium Azide.

Shipped at 4°C. Upon delivery aliquot and store at -20°C. Avoid freeze / thaw cycles.

Cf7, Coagulation factor VII, coagulation factor VII (serum prothrombin conversion accelerator), Eptacog alfa, F7, F7 deficiency, FA7_HUMAN, Factor VII deficiency, Factor VII heavy chain, Factor VII light chain, FVII, FVII coagulation protein, Hypoproconvertinemia, OTTHUMP00000018733, OTTHUMP00000018734, Proconvertin, Serum prothrombin conversion accelerator, SPCA